Ronald Baum
Examiner (ID: 9396, Phone: (571)272-3861 , Office: P/2439 )
Most Active Art Unit | 2439 |
Art Unit(s) | 2135, 2439, 2131, 2139, 2136 |
Total Applications | 545 |
Issued Applications | 358 |
Pending Applications | 59 |
Abandoned Applications | 128 |
Applications
Application number | Title of the application | Filing Date | Status |
---|---|---|---|
Array
(
[id] => 16915683
[patent_doc_number] => 20210188775
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS
[patent_app_type] => utility
[patent_app_number] => 17/249457
[patent_app_country] => US
[patent_app_date] => 2021-03-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 48246
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -31
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17249457
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/249457 | CARBOXAMIDE AND SULFONAMIDE DERIVATIVES USEFUL AS TEAD MODULATORS | Mar 1, 2021 | Pending |
Array
(
[id] => 16915702
[patent_doc_number] => 20210188794
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => PROCESS FOR PRODUCING 2,5-FURANDICARBOXYLIC ACID DIALKYL ESTER
[patent_app_type] => utility
[patent_app_number] => 17/188751
[patent_app_country] => US
[patent_app_date] => 2021-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9000
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 104
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188751
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/188751 | PROCESS FOR PRODUCING 2,5-FURANDICARBOXYLIC ACID DIALKYL ESTER | Feb 28, 2021 | Abandoned |
Array
(
[id] => 16915703
[patent_doc_number] => 20210188795
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => MULTI-STAGE ESTERIFICATION PROCESS
[patent_app_type] => utility
[patent_app_number] => 17/188914
[patent_app_country] => US
[patent_app_date] => 2021-03-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6080
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 189
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17188914
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/188914 | MULTI-STAGE ESTERIFICATION PROCESS | Feb 28, 2021 | Abandoned |
Array
(
[id] => 17067196
[patent_doc_number] => 20210269411
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-02
[patent_title] => COMFREYNS, ARYLNAPHTHALENE LIGNANS THAT INHIBIT PRO-INFLAMMATORY GENE EXPRESSION, AND PHARMACEUTIC COMPOSITION COMPRISING THEM
[patent_app_type] => utility
[patent_app_number] => 17/185308
[patent_app_country] => US
[patent_app_date] => 2021-02-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14330
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 52
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17185308
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/185308 | COMFREYNS, ARYLNAPHTHALENE LIGNANS THAT INHIBIT PRO-INFLAMMATORY GENE EXPRESSION, AND PHARMACEUTIC COMPOSITION COMPRISING THEM | Feb 24, 2021 | Pending |
Array
(
[id] => 18716487
[patent_doc_number] => 11793808
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-10-24
[patent_title] => Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them
[patent_app_type] => utility
[patent_app_number] => 17/181448
[patent_app_country] => US
[patent_app_date] => 2021-02-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13963
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 102
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17181448
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/181448 | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them | Feb 21, 2021 | Issued |
Array
(
[id] => 17050608
[patent_doc_number] => 20210260042
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR REDUCING REDNESS AND INCREASING WHITENESS IN EYES AND OTHER OPHTHALMIC PURPOSES
[patent_app_type] => utility
[patent_app_number] => 17/180545
[patent_app_country] => US
[patent_app_date] => 2021-02-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37614
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 44
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17180545
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/180545 | ALPHA-2-ADRENERGIC RECEPTOR AGONISTS FOR REDUCING REDNESS AND INCREASING WHITENESS IN EYES AND OTHER OPHTHALMIC PURPOSES | Feb 18, 2021 | Abandoned |
Array
(
[id] => 16869990
[patent_doc_number] => 20210163457
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/172861
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15117
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 29
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172861
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/172861 | CANAGLIFLOZIN MONOHYDRATE AND ITS CRYSTALLINE FORMS, PREPARATION METHODS AND USES THEREOF | Feb 9, 2021 | Abandoned |
Array
(
[id] => 16873955
[patent_doc_number] => 20210167422
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => LIQUID ELECTROLYTE FOR BATTERY
[patent_app_type] => utility
[patent_app_number] => 17/172760
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 3054
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 66
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17172760
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/172760 | Liquid electrolyte for battery | Feb 9, 2021 | Issued |
Array
(
[id] => 16870048
[patent_doc_number] => 20210163515
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => BENFOTIAMINE DERIVATIVES IN THE TREATMENT OF ALZHEIMER'S DISEASE
[patent_app_type] => utility
[patent_app_number] => 17/173059
[patent_app_country] => US
[patent_app_date] => 2021-02-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5993
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17173059
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/173059 | Benfotiamine derivatives in the treatment of alzheimer's disease | Feb 9, 2021 | Issued |
Array
(
[id] => 19043570
[patent_doc_number] => 11932654
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-19
[patent_title] => Nimbolide analogs as anti-cancer agents and preparation thereof
[patent_app_type] => utility
[patent_app_number] => 17/171276
[patent_app_country] => US
[patent_app_date] => 2021-02-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 7147
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17171276
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/171276 | Nimbolide analogs as anti-cancer agents and preparation thereof | Feb 8, 2021 | Issued |
Array
(
[id] => 18329191
[patent_doc_number] => 11634419
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-25
[patent_title] => Dimethyl amino azetidine amides as JAK inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/248717
[patent_app_country] => US
[patent_app_date] => 2021-02-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 24194
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17248717
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/248717 | Dimethyl amino azetidine amides as JAK inhibitors | Feb 3, 2021 | Issued |
Array
(
[id] => 16854883
[patent_doc_number] => 20210155628
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-27
[patent_title] => Heterocyclic Compounds as RET Kinase Inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/165151
[patent_app_country] => US
[patent_app_date] => 2021-02-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38370
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -28
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17165151
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/165151 | Heterocyclic compounds as RET kinase inhibitors | Feb 1, 2021 | Issued |
Array
(
[id] => 17050602
[patent_doc_number] => 20210260036
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-08-26
[patent_title] => METHODS OF TREATMENT FOR ALPHA-1 ANTITRYPSIN DEFICIENCY
[patent_app_type] => utility
[patent_app_number] => 17/162129
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16911
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 38
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17162129
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/162129 | METHODS OF TREATMENT FOR ALPHA-1 ANTITRYPSIN DEFICIENCY | Jan 28, 2021 | Pending |
Array
(
[id] => 16839442
[patent_doc_number] => 20210147454
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => COT MODULATORS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/162754
[patent_app_country] => US
[patent_app_date] => 2021-01-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 26534
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -2
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17162754
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/162754 | Cot modulators and methods of use thereof | Jan 28, 2021 | Issued |
Array
(
[id] => 17761467
[patent_doc_number] => 20220235079
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-07-28
[patent_title] => Crystalline Forms of Tenofovir Alafenamide
[patent_app_type] => utility
[patent_app_number] => 17/159238
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7994
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159238
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/159238 | Crystalline forms of Tenofovir alafenamide | Jan 26, 2021 | Issued |
Array
(
[id] => 16824156
[patent_doc_number] => 20210139449
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => CONVERSION OF CANNABIDIOL OR DELTA-9 TETRAHYDROCANNABINOLIC ACID TO DELTA-9 TETRAHYDROCANNABINOL AND DELTA-8 TETRAHYDROCANNABINOL IN NONTOXIC HETEROGENEOUS MIXTURES
[patent_app_type] => utility
[patent_app_number] => 17/157078
[patent_app_country] => US
[patent_app_date] => 2021-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5673
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 180
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17157078
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/157078 | CONVERSION OF CANNABIDIOL OR DELTA-9 TETRAHYDROCANNABINOLIC ACID TO DELTA-9 TETRAHYDROCANNABINOL AND DELTA-8 TETRAHYDROCANNABINOL IN NONTOXIC HETEROGENEOUS MIXTURES | Jan 24, 2021 | Abandoned |
Array
(
[id] => 16839376
[patent_doc_number] => 20210147388
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/155244
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41543
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -70
[patent_words_short_claim] => 559
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17155244
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/155244 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | Jan 21, 2021 | Pending |
Array
(
[id] => 16839405
[patent_doc_number] => 20210147417
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-20
[patent_title] => PROCESSES FOR PREPARING AN FGFR INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 17/155726
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11041
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17155726
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/155726 | PROCESSES FOR PREPARING AN FGFR INHIBITOR | Jan 21, 2021 | Pending |
Array
(
[id] => 16945900
[patent_doc_number] => 20210204591
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-08
[patent_title] => TERPENES AND THC COMPOSITIONS AND METHODS
[patent_app_type] => utility
[patent_app_number] => 17/248047
[patent_app_country] => US
[patent_app_date] => 2021-01-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11490
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17248047
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/248047 | TERPENES AND THC COMPOSITIONS AND METHODS | Jan 5, 2021 | Pending |
Array
(
[id] => 18329173
[patent_doc_number] => 11634401
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-25
[patent_title] => Process-scale synthesis of urolithin A
[patent_app_type] => utility
[patent_app_number] => 17/141472
[patent_app_country] => US
[patent_app_date] => 2021-01-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 8041
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 73
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17141472
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/141472 | Process-scale synthesis of urolithin A | Jan 4, 2021 | Issued |